[SUN-154] The Effects of Vitamin D and Calcium Supplementation on Cardiovascular Risk in Adults at High Risk for Diabetes

Joanna Mitri, Bess Dawson-Hughes, Frank Hu, Anastassios G Pittas. Tufts Medical Center, Boston, MA; Jean Mayer US Department of Agriculture Human Nutrition Research Center on Aging, Tufts University, Boston, MA; Harvard School of Public Health, Boston, MA and Channing Laboratory, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA.

Background: Observational studies suggest that vitamin D deficiency may modify risk of cardiovascular disease. However, the effect of vitamin D supplementation on cardiovascular risk factors in persons at risk for diabetes is unknown.
Objective: To determine whether vitamin D supplementation, with or without calcium, has an effect on lipid profile, endothelial markers, or blood pressure in adults at high risk for diabetes.
Design, setting and patients: Randomized placebo-controlled trial of ninety two adults with pre-diabetes randomized in a 2-by-2 factorial design to either cholecalciferol (2,000 international units once daily) or calcium carbonate (400 mg twice daily) for 16 weeks.
Outcomes: Change in total, LDL and HDL cholesterol, triglycerides, triglycerides to HDL ratio; endothelial markers (ICAM, VCAM and E-selectin); systolic and diastolic blood pressure over 16 weeks.
Results: Participants had a mean age of 57 years, BMI of 32 kg/m2 and hemoglobin A1c of 5.9%. There was no significant vitamin D x calcium interaction on any outcome. After adjustment for age, race, time of study entry, body fat percentage and physical activity, triglyceride concentration was lower in the vitamin D group compared to the no vitamin D group (adjusted mean change±SEM -21.3±9.1 mg/dl for vitamin D vs. 4.4±8.5 for no vitamin D; p=0.021). The triglyceride-HDL ratio was also in the same direction (0.62±0.27 mg/dl for vitamin D vs. 0.21±0.26 for no vitamin D; p=0.014). There was no significant difference in the change in total, LDL or HDL cholesterol between vitamin D groups. E-selectin change was lower in the vitamin D group compared to the no vitamin D group (-2.9 ±0.8 ng/ml for vitamin D vs. -0.7±0.8 for no vitamin D; p= 0.042) and there was no difference in change in ICAM or VCAM. There was no difference in change in blood pressure in any group. There were no differences in any of the outcomes between the calcium vs. no calcium groups.
Conclusion: In adults at risk for diabetes, short-term supplementation with cholecalciferol improved triglycerides, triglyceride-HDL ratio and E-selectin but had no effect on other vascular markers or blood pressure.

Sources of Research Support: NIH Research grant R01DK76092 (to AGP, funded by the National Institute of Diabetes and Digestive and Kidney Disease, and the NIH Office of Dietary Supplements); UL1 RR025752 (to Tufts Medical Center) from the National Center for Research Resources; the U.S. Department of Agriculture Cooperative Agreement No. 58-1950-4-401 (to BDH) and the Endocrine Fellows Foundation grant (to JM). Calcium carbonate pills and matching placebos were donated by Glaxo-Smith-Kline, Parsippany, NJ.

Nothing to Disclose: JM, BD-H, FH, AGP

Date: Sunday, June 24, 2012
Session Info: POSTER SESSION: Cardiometabolic Risk (1:30 PM-3:30 PM)
Presentation Time: 1:30 pm
Room: Expo

Embargo Policy
Unless otherwise noted, all abstracts presented at ENDO are embargoed until the date and time of presentation. Abstracts presented at a news conference are embargoed until the date and time of the news conference. The Endocrine Society reserves the right to lift the embargo on specific abstracts that are selected for promotion prior to or during ENDO.

Disclaimer Statement
The information presented at ENDO news conferences and within the Research Summaries Book represents the opinion of the presenters and authors and is not necessarily the view of The Endocrine Society. The Endocrine Society makes no representation as to the truth or warranty, accuracy, or originality of the information presented.

For additional information, please contact The Endocrine Society’s Public Affairs Department at 240-482-1380 or alohr@endo-society.org.


Close Window